490 related articles for article (PubMed ID: 35139916)
1. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.
Jakova E; Moutaoufik MT; Lee JS; Babu M; Cayabyab FS
Transl Neurodegener; 2022 Feb; 11(1):9. PubMed ID: 35139916
[TBL] [Abstract][Full Text] [Related]
2. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
3. Long-term adenosine A1 receptor activation-induced sortilin expression promotes α-synuclein upregulation in dopaminergic neurons.
Lv YC; Gao AB; Yang J; Zhong LY; Jia B; Ouyang SH; Gui L; Peng TH; Sun S; Cayabyab FS
Neural Regen Res; 2020 Apr; 15(4):712-723. PubMed ID: 31638096
[TBL] [Abstract][Full Text] [Related]
4. Protein phosphatase role in adenosine A1 receptor-induced AMPA receptor trafficking and rat hippocampal neuronal damage in hypoxia/reperfusion injury.
Stockwell J; Chen Z; Niazi M; Nosib S; Cayabyab FS
Neuropharmacology; 2016 Mar; 102():254-65. PubMed ID: 26626486
[TBL] [Abstract][Full Text] [Related]
5. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
[TBL] [Abstract][Full Text] [Related]
7. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
8. Prolonged adenosine A1 receptor activation in hypoxia and pial vessel disruption focal cortical ischemia facilitates clathrin-mediated AMPA receptor endocytosis and long-lasting synaptic inhibition in rat hippocampal CA3-CA1 synapses: differential regulation of GluA2 and GluA1 subunits by p38 MAPK and JNK.
Chen Z; Xiong C; Pancyr C; Stockwell J; Walz W; Cayabyab FS
J Neurosci; 2014 Jul; 34(29):9621-43. PubMed ID: 25031403
[TBL] [Abstract][Full Text] [Related]
9. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
10. ATPase Thorase Deficiency Causes α-Synucleinopathy and Parkinson's Disease-like Behavior.
Gao F; Zhang H; Yang J; Cai M; Yang Q; Wang H; Xu Y; Chen H; Hu Y; He W; Zhang J
Cells; 2022 Sep; 11(19):. PubMed ID: 36230952
[TBL] [Abstract][Full Text] [Related]
11. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
12. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
[TBL] [Abstract][Full Text] [Related]
14. Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.
Thakur P; Breger LS; Lundblad M; Wan OW; Mattsson B; Luk KC; Lee VMY; Trojanowski JQ; Björklund A
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8284-E8293. PubMed ID: 28900002
[TBL] [Abstract][Full Text] [Related]
15. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.
Luna E; Luk KC
FEBS Lett; 2015 Dec; 589(24 Pt A):3749-59. PubMed ID: 26505673
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A
Cai Q; Xu N; He Y; Zhu J; Ye F; Luo Z; Lu R; Huang L; Zhang F; Chen JF; Li Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674880
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of adenosine A1 receptor on pain-related behavior in normal and nerve-injured rats.
Gong QJ; Li YY; Xin WJ; Wei XH; Cui Y; Wang J; Liu Y; Liu CC; Li YY; Liu XG
Brain Res; 2010 Nov; 1361():23-30. PubMed ID: 20850420
[TBL] [Abstract][Full Text] [Related]
18. A Positive Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model.
Imlach WL; Bhola RF; May LT; Christopoulos A; Christie MJ
Mol Pharmacol; 2015 Sep; 88(3):460-8. PubMed ID: 26104547
[TBL] [Abstract][Full Text] [Related]
19. GV-971 attenuates α-Synuclein aggregation and related pathology.
Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
[TBL] [Abstract][Full Text] [Related]
20. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
